• Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.

• The figures for Bio Medica Laboratories Limited are based on the standalone restated results for the period ended March 31, 2025.

• The figures for the peer group are based on standalone audited results for the period ended March 31, 2025.

• Current Market Price (CMP) is the closing price of respective scrip as on 8th May, 2026.

• PE ratio have been taken as on 8th May, 2026.

For further details see section titled Risk Factors beginning on page 21 and the financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 243 of this Prospectus for a more informed view.

Our company considers that KPIs included herein below have a bearing for arriving at the basis for Offer Price. The KPI s disclosed below have been app roved by a resolution of our Audit Committee dated December 27, 2025, Further, the KPIs herein have been certified by M/s Vijay K Jain & Associates, Chartered Accountants, by their certificate dated January 27,2026, vide UDIN 26429107UIKSQA7214. Additionally, the Audit Committee on its meeting dated December 27,2025, have confirmed that other than verified and audited KPIs set out below, our company has not disclosed to earlier investors at any point of time during the three years period prior to the date of the Prospectus.

For further details of our key performance indicators, see "Risk Factors, "Our Business", "Management's Discussion and Analysis of Financial Condition and Results of Operations" on pages 21,155 and 245 respectively. We have described and defined them, where applicable, in "Definitions and Abbreviations" section on page 2. Our Company confirms that it shall continue to disclose all the KPIs included in this section "Basis for Offer Price", on a periodic basis, at least once in a year (or for any lesser period as determined by the Board of our Company), for a duration that is at least the later of (i) one year after the listing date or period specified by SEBI; or (ii) till the utilization of the Net Proceeds. Any change in these KPIs, during the aforementioned period, will be explained by our Company as required under the SEBI ICDR Regulations.

Key metrics like revenue growth, EBIDTA Margin, PAT Margin and few balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company. Restated KPI indicators

The Issue was being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBIICDR Regulations, as amended, wherein not more than 50% of the Net Issue was available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBS", the "QIB Portion"), Our Company in consultation with the Book Running Lead Manager has allocated upto 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). Further, not less than 15% of the Net Issue was made available for allocation on a proportionate basis to Non-Institutional Bidders (out of which one third was reserved for applicants with an application size of more than two lots and upto such lots equivalent to not more 10,00,000 and two- thirds was reserved for applicants with application size of more than 10,00,000) and not less than 35% of the Net Issue was made available for allocation to Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. Further, Equity Shares were allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Issue through the ASBA process. For details, see" Issue Procedure "beginning on page 311 of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the NSE Limited. The trading is proposed to be commenced on or before May 29, 2026*

*Subject to the receipt of listing and trading approval from the NSE ("NSE Emerge").

*Note: The issue does not include Anchor Investors

The Issue (excluding Anchor Investors Portion) received 3,091 Applications for 37,72,000 Equity Shares (before technical rejections) resulting in 3.23 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

A summary of the final demand as per NSE as on the Bid/Issue Closing Date at different Bid prices is as under:

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being NSE Limited on May 26, 2026.

1. Allotments Individual Investors (After Technical Rejections)

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 139/- per Equity Share, was finalized in consultation with NSE Limited. The category has been subscribed to the extent of 2.88 times. The total number of Equity Shares Allotted in this category is 17,92,000 Equity Shares to 896 successful applicants. The details of the Basis of Allotment of the said category is as under:

2. Allotment to Non-Institutional Investors-Above Rs. 2 Lakhs and Upto Rs.10 Lakhs (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 139/- per Equity Share, was finalized in consultation with NSE Limited. The category has been subscribed to the extent of 1.69 times. The total number of Equity Shares Allotted in this category is 7,51,000 Equity Shares to 250 successful applicants. The details of the Basis of Allotment of the said category is as under:

3. Allotment to Non-Institutional Investors-Above Rs. 10 Lakhs (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 139/- per Equity Share, was finalized in consultation with NSE Limited. The category has been subscribed to the extent of 0.86 times. The total number of Equity Shares Allotted in this category is 10,04,000 Equity Shares to 34 successful applicants. The details of the Basis of Allotment of the said category is as under:

4. Allotment to QIBs excluding Anchor Investors (After Technical Rejections)

Allotment to QIBs, who have bid at the Issue Price of Rs. 139/- per Equity Share or above, has been done on a proportionate basis in consultation with NSE Limited. This category has been subscribed to the extent of 15.94 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 36,000 Equity Shares, which were allotted to 6 successful Applicants.

5) Allocation to Market Maker (After Technical Rejections & Withdrawal): The Basis of Allotment to Market Maker who have bid at Issue Price of Rs. 139/- per Equity Shares or above, was finalized in consultation with NSE Limited. The category was subscribed 1.00 times i.e. for 1,89,000 Equity Shares the total number of shares allotted in this category is 1,89,000 Equity Shares. The category wise details of the Basis of Allotment are asunder:

6. Allotment to Anchor Investors (After Technical Rejections)

The Company in consultation with the BRLM has allocated (Nil) Equity Shares to Anchor Investors at the Anchor Investor issue price of Rs. 139/- per Equity Shares in accordancewiththeSEBI ICDR Regulations. This represents 60% of the QIB Category.

The Board of Directors of our Company at its meeting held on May 26, 2026, has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being NSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/ mailed for unblocking of funds and transfer to the Public Issue Account on or before May 27, 2026, and payment to non-Syndicate brokers have been issued on May 27, 2026. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from NSE Limited and the trading of the Equity Shares is expected to commence on May 29, 2026.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated May 26, 2026 ("Prospectus").

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, Skyline Financial Services Private Limited at www.skylinerta.com

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

	SKYLINE FINANCIAL SERVICES PRIVATE LIMITED
	D-153 A, 1st Floor, Okhla Industrial Area, Phase -1, New Delhi-110020
	Contact Person: Mr. Anuj Rana
	Tel: +91-11-40450193-97
	Fax: N.A
	Email: ipo@skylinerta.com
	Website: www.skylinerta.com
	SEBI Registration No.: INR000003241
		On behalf of Board of Directors
		FOR BIO MEDICA LABORATORIES LIMITED
		Sd/-
Place: Indore		Pradeep Mehta
Date: May 27, 2026		(Managing Director)

Disclaimer: Bio Medica Laboratories Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Gwalior, on May 26, 2026, and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of NSE EMERGE at http://www.nseindia.com/market-data/all-upcoming-issues-ipo and is available on the websites of the BRLM at www.narnolia.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 21 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the a transaction not subject to, the registration requirements of the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.